Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17483
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHayley, Amie C-
dc.contributor.authorStough, Con-
dc.contributor.authorDowney, Luke A-
dc.date2017-06-27-
dc.date.accessioned2018-04-20T00:49:46Z-
dc.date.available2018-04-20T00:49:46Z-
dc.date.issued2017-
dc.identifier.citationEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2017; 27(8): 732-743-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17483-
dc.description.abstractCannabis use disorder (CUD) is frequently associated with concurrent substance use and/or comorbid substance use disorders (SUDs); however there is little specificity with regard to commonly abused individual drug types/classes. This study therefore aimed to provide insight into the degree of these co-occurring relationships across several specific newer and older generation illicit and prescription drugs. 36,309 adults aged 18+ from wave 3 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III) were assessed. Weighted cross-tabulations and multivariable logistic regression analyses were used to evaluate comorbidity between current DSM-5 CUD, substance use and DSM-5 SUD. Current DSM-5 CUD is associated with greater lifetime use of all examined drug classes, and previous 12-month use of several newer-class illicit and prescription stimulant-based substances (all p< 0.05). Current DSM-5 CUD was similarly associated with increased incidence of a range of DSM-5 SUDs and was independently associated with concurrently reporting current DSM-5; sedative (Adjusted OR= 5.1, 95%CI 2.9-9.0), cocaine (AOR= 9.3, 95%CI 5.6-15.5), stimulant (AOR= 4.3, 95%CI 2.3-7.9), club drug (AOR= 16.1, 95%CI 6.3-40.8), opioid (AOR= 4.6, 95%CI 3.0-6.8) and alcohol-use disorder (AOR= 3.0, 95%CI 2.5-3.7); but not heroin or 'other' drug use disorder (both p>0.05). High comorbidity exists between DSM-5 CUD and many specific DSM-5 SUDs. Newer-class illicit and prescription stimulant-based drug use disorders are overrepresented among those with DSM-5 CUD. These findings underscore the need for tailored treatment programs for those presenting with DSM-5 CUD, and for greater treatment specification where poly-drug use is evident.-
dc.language.isoeng-
dc.subjectCannabis use disorder-
dc.subjectDSM-5-
dc.subjectIllicit-
dc.subjectNESARC-
dc.subjectPrescription-
dc.subjectSubstance use disorder-
dc.titleDSM-5 cannabis use disorder, substance use and DSM-5 specific substance-use disorders: Evaluating comorbidity in a population-based sample.-
dc.typeJournal Article-
dc.identifier.journaltitleEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology-
dc.identifier.affiliationCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Australia-
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1016/j.euroneuro.2017.06.004-
dc.identifier.pubmedid28663122-
dc.type.austinJournal Article-
local.name.researcherHayley, Amie C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.